Xbiotech (XBIT) Fundamental Analysis: Revenue, Earnings & Valuation

6.59 / 10

Outperform

Fundamental analysis rates XBIT as Outperform with a 6.6/10 score. Strengths include a high interest‑coverage ratio and favorable Revenue‑MV, while current‑liabilities‑to‑total‑liabilities and PB‑ROE are weak. Overall fund‑score 6.59 reflects solid asset and revenue metrics.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight32.80%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.45%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.74%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value81.47

Score1/3

Weight-5.23%

1M Return-1.69%

PB-ROE

Value-0.58

Score1/3

Weight26.51%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.02

Score2/3

Weight-1.16%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.80%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.18%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.59%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight57.59%

1M Return11.61%

Is XBIT fundamentally strong?

XBIT scores 6.59/10 on fundamentals and holds a Discounted valuation at present. Backed by its -28.23% ROE, 0.00% net margin, -1.57 P/E ratio, 0.51 P/B ratio, and -18.25% earnings growth, these metrics solidify its Outperform investment rating.